BIOEQUIVALENCE and STATISTICS in CLINICAL PHARMACOLOGY

Bioequivalence and Statistics in Clinical Pharmacology

Volumn , Issue , 2005, Pages 1-374

  Patterson, Scott ^a   Jones, Byron ^b  

^a GLAXOSMITHKLINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85151658801     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420034936     Document Type: Book

References (473)

1. Aarons, L., Karlsson, M., Mentre, F., Rombout, F., Steimer, J.-L., van Peer, A., and Invited COST B15 Experts (2001) The role of modelling and simulation in phase I drug development. European Journal of Pharmaceutical Sciences, 13, 115-122.
2. Akaike, H. (1973) Information theory and an extension of the maximum likelihood principle. Second International Symposium on Information Theory, 267-281.
3. Altman, D.G., Bland, J.M. (1983) Measurement in medicine: the analysis of method comparison studies. The Statistician, 32, 307-317.
4. Altman, D.G., Bland, J.M. (1995) Absence of evidence is not evidence of absence. British Medical Journal, 311, 485.
5. Amankwa, A., Krishnan, S., Tisdale, J. (2004) Torsades de pointes associated with fluoroquinilones: importance of concommitant risk factors. Clinical Pharmacology and Therapeutics, 75(3), 242-7.
6. Anderson, S. (1993) Individual bioequivalence: a problem of switchability [with discussion]. Biopharmaceutical Reports, 2, 1-11.
7. Anderson, S. (1995) Current issues in individual bioequivalence. Drug Information Journal, 29, 961-964.
8. Anderson, S., Hauck W.W. (1983) A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Communications in Statistical Theory and Methods, 12, 2663-2692.
9. Anderson, S., Hauck W.W. (1990) Consideration of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 18, 259-273.
10. Anderson, S., Hauck W.W. (1996) The transitivity of bioequivalence testing: potential for drift. International Journal of Clinical Pharmacology and Therapeutics, 34, 369-374.
11. Ansbacher, R. (1990) Interchangeability of low dose oral contraceptives. Contraception, 43, 139-147.
12. Atkinson, A., Daniels, C., Dedrick, R., Grudzinskas, C., Markey, S., eds. (2001) Principles of Clinical Pharmacology. Academic Press, San Diego.
13. Australia Therapeutic Goods Administration, Australian Regulatory Guidelines for Prescription Medicines (2002) Appendix 15, Biopharmaceutical Studies.
14. Balakrishnan, N., Ma, C.W. (1990) A comparative study of various tests for the equality of two population variances. Journal of Statistical Computing and Simulation, 35, 41-89.
15. Balthasar, J.P. (1999) Bioequivalence and bioequivalency testing. American Journal of Pharmaceutical Education, 63, 194-198.
16. Barbieri M.M., Liseo, B., Petrella, L. (2000) Bayes factors for Fieller’s problem. Biometrika, 87, 717-723.
17. Barrett, J.S., Batra, V., Chow, A., Cook, J., Gould, A.L., Heller, A., Lo, M.-W., Patterson, S.D., Smith, B.P., Stritar, J.A., Vega, J.M., Zariffa, N. (2000) PhRMA perspective on population and individual bioequivalence and update to the PhRMA perspective on population and individual bioequivalence. Journal of Clinical Pharmacology, 40, 561-572.
18. Bartlett, M.S. (1936) Properties of sufficiency and statistical tests. Proceedings of the Royal Statistical Society, Series A, 154, 124-137.
19. Basson, R.P., Ghosh, A., Cerimele, B.J., DeSante, K.A., Howey, D.C. (1998)Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate. Pharmaceutical Research, 15, 276-279.
20. Bauer, P. (1991) Multiple testing in clinical trials. Statistics in Medicine, 10, 871-890.
21. Bauer, P., Bauer, M.M. (1994) Testing equivalence simultaneously for location and dispersion of two normally distributed populations. Biometrical Journal, 6, 643-660.
22. Bauer, P., Kieser, M. (1996) A unifying approach for confidence intervals and testing of equivalence and difference. Biometrika, 83, 934-937.
23. Bazett, H. (1920) An analysis of time relations of electrocardiograms. Heart, 7, 353-367.
24. Bekersky, I., Dressler, D., Colburn, W., Mekki, Q. (1999) Bioequivalence of 1 and 5 mg Tacrolimus capsules using a replicate study design. Journal of Clinical Pharmacology, 39, 1032-1037.
25. Bellavance, F., Tardif, S. (1995) A nonparametric approach to the analysis of three-treatment three-period cross-over data. Biometrika, 82, 865-875.
26. Benet, L.Z., Goyan, J.E. (1995) Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy, 15, 433-440.
27. Benet, L.Z. (1999) Understanding bioequivalence testing. Transplantation Proceedings, 31, Suppl A, 7S-9S.
28. Berger, R.L. (1992) Multiparametric hypothesis testing and acceptance sampling. Technometrics, 24, 295-300.
29. Berger, R.L., Hsu, J.C. (1996) Bioequivalence trials, intersection- union tests, and equivalence confidence sets. Statistical Science, 11, 283-319.
30. Bhoj, D.S. (1979) Testing equality of variances of correlated variates with incomplete data on both responses. Biometrika, 66, 681-683.
31. Bickel, P.J., Doksum, K.A. (1977) Mathematical Statistics. Holden Day, San Francisco.
32. Biomarker Definition Working Group (2001) Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69, 89-95.
33. Blackwelder, W.C. (1982) Proving the null hypothesis in clinical trials. Controlled Clinical Trials, 3, 345-353.
34. Blume, H.H., Midha, K.K., eds. (1993) Conference Report. In:Bio-International: Bioavailability, Bioequivalence, and Pharmacokinetics. Medpharm Stuttgart, 13-23.
35. Boddy, A.W., Snikeris, F.C., Kringle, R.O., Wi, G.C.-G., Oppermann, J.A., Midha, K.K. (1995) An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs. Pharmaceutical Research, 12, 1865-1868.
36. Bois, F.Y., Tozer, T.N., Hauck, W.W., Chen, M.L., Patnaik, R., Williams, R. (1994) Bioequivalence: Performance of several measures of extent of absorption. Pharmaceutical Research, 11, 715-722.
37. Bonate, P., Howard, D., eds. (2004) Pharmacokinetics in Drug Development: Clinical Study Design and Analysis. AAPS Press, Arlington, VA.
38. Box, G.E., Cox, D.R. (1964) An analysis of transformations. Journal of the Royal Statistical Society, Series B, 26, 211-243.
39. Box, G.E. (1966) Use and abuse of regression. Technometrics, 8, 625-629.
40. Box, G.E. (1979) Robustness in the strategy of scientific model building. In Robustness in Statistics, Launer, R.L., Wilkinson, G.N., eds., 201-236. Academic Press: New York.
41. Boxtel, C., Holford, N., Danhof, M., eds. (1992) The In Vivo Study of Drug Action. Elsevier, NY.
42. Breslow, N. with discussion (1990) Biostatistics and Bayes. Statistical Science, 5, 269-298.
43. Bristol, D.R. (1991a) Testing equality of treatment variances in a 2×2 cross-over study. Journal of Biopharmaceutical Statistics, 1, 185-192.
44. Bristol, D.R. (1991b) A confidence interval for the ratio of treatment variances in a 2 × 2 cross-over study. Journal of Biopharmaceutical Statistics, 1, 237-245.
45. Brown, B.W. (1980) The cross-over experiment for clinical trials. Biometrics, 36, 69-79.
46. Brown, E.B., Iyer, H.K., Wang, C.M. (1997) Tolerance intervals for assessing individual bioequivalence. Statistics in Medicine, 16, 803-820.
47. Brown, H.K., Kempton, R.A. (1994) The application of REML in clinical trials. Statistics in Medicine, 13, 1601-1617.
48. Brown, L.D., Hwang, J.T.G., Munk, A. (1997) An unbiased test for the bioequivalence problem. Annals of Statistics, 25, 2345-2367.
49. Brown, L.B., Casella, G., Hwang, G. (1995) Optimal confidence sets, bioequivalence, and the limacon of Pascal. Journal of the American Statistical Association, 90, 880-889.
50. Brown, M.B., Forsythe, A.B. (1974) Robust tests for the equality of variances. Journal of the American Statistical Association, 69, 364-367.
51. Buice, R.G., Subramanian, V.S., Duchin, K.L., Uko-Nne, S. (1996) Bioequivalence of a highly variable drug: An experience with Nadolol. Pharmaceutical Research, 13, 1109-1115.
52. Burdick, R.K., Graybill, F.A. (1992) Confidence Intervals on Variance Components. Marcel Dekker, NY.
53. Burdick, R.K., Sielken, R.L. (1978) Exact confidence intervals for linear combinations of variance components in nested classifications. Journal of the American Statistical Association, 73, 632-635.
54. Burnham, R. (2005) The man who remade the universe. Astronomy, 33, 39-41.
55. Burzykowski, T., Molenberghs, G., Buyse, M., eds. (2005) The Evaluation of Surrogate Endpoints Springer, NY.
56. Calvert, R.T. (1996) Bioequivalence and generic prescribing: a pharmacy view. Journal of Pharmacy and Pharmacology, 48, 9-10.
57. Canadian Guidance for Industry (1992) Conduct and Analysis of Bioequivalence Studies - Part A.
58. Canadian Guidance for Industry (1996) Conduct and Analysis of Bioequivalence Studies - Part B.
59. Canafax, D.M., Irish, W.D., Moran, H.B., Squiers, E., Levy, R., Pouletty, P., First, M.R., Christians, U. (1999) An individual bioequivalence approach to compare the intra-subject variability of two Ciclosporin formulations, SangCya and Neoral. Pharmacology, 59, 78-88.
60. Carter, B.L., Noyes, M.A., Demmler, R.W. (1993) Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy, 13, 359-368.
61. Cartwright, A.C. (1991) International harmonisation and consensus DIA meeting on bioavailability and bioequivalence requirements and standards. Drug Information Journal, 25, 471-482.
62. Casella, G., George, E.J. (1992) Explaining the Gibbs sampler. The American Statistician, 46, 167-174.
63. Cerutti, R., Rivolta, G., Cavalieri, L., Di Giulio, C., Grossi, E., Vago, T., Baldi, G., Righini, V., Marzo, A. (1999) Bioequivalence of Levothyroxine tablets administered to a target population in steady state. Pharmacological Research, 39, 193-201.
64. Chaturvedi, A., Bhatti, M.I., Kumar, K. (2000) Bayesian analysis of disturbances variance in the linear regression model under assymetric loss assumptions. Applied Mathematics and Computation, 114, 149-153.
65. Chen, K-W., Li, G., Sun, Y. (1996) A confidence region approach for assessing equivalence in variability of bioavailability. Biometrical Journal, 4, 475-487.
66. Chen, M.-L. (1997) Individual bioequivalence - a regulatory update. Journal of Biopharmaceutical Statistics, 7, 5-11.
67. Chen, M.-L., Patnaik, R., Hauck, W.H., Schuirmann, D.J., Hyslop, T., Williams, R. (2000a) An individual bioequivalence criterion:regulatory considerations. Statistics in Medicine, 19, 2821-2842.
68. Chen, M.-L., Lee, S-C., Ng, M-J., Schuirmann, D., Lesko, L.J., Williams, R.L. (2000b) Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clinical Pharmacology and Therapeutics, 68, 510-521.
69. Chi, E.M. (1994) M-estimation in cross-over trials. Biometrics, 50, 486-493.
70. China State Drug Administration (2003) Drug Registration Regulation.
71. Chinchilli, V.M. (1996) The assessment of individual and population bioequivalence. Journal of Biopharmaceutical Statistics, 6, 1-14.
72. Chinchilli, V.M., Elswick, R.K. (1997) The multivariate assessment of bioequivalence. Journal of Biopharmaceutical Statistics, 7, 113-123.
73. Chinchilli, V.M., Esinhart, J.D. (1996) Design and analysis of intra-subject variability in cross-over experiments. Statistics in Medicine, 15, 1619-1634.
74. Chow, S.C., Liu, J. (2000) Design and Analysis of Bioavailability and Bioequivalence Studies, 2ed. Marcel Dekker, New York.
75. Chow, S.C., Shao, J. (1988) A new procedure for the estimation of variance components. Statistics and Probability Letters, 6, 349-355.
76. Chow, S.C., Shao, J., Wang, H. (2002a) Individual bioequivalence testing under 2 × 3 designs. Statistics in Medicine, 21, 629-48.
77. Chow, S.C., Shao, J., Hu, O. (2002b) Assessing sensitivity and similarity in bridging studies. Journal of Biopharmaceutical Statistics, 12, 385-400.
78. Colaizzi, J.L., Lowenthal, D.T. (1986) Critical therapeutic categories:A contraindication to generic substitution? Clinical Therapeutics, 8, 370-379.
79. Colburn, W.A., Keefe, D.L. (2000) Bioavailability and bioequivalence:Average, population, and/or individual. Journal of Clinical Pharmacology, 40, 559-600.
80. Conforti, M., Hochberg, Y. (1987) Sequentially rejective pairwise testing procedures. Journal of Statistical Planning and Inference, 17, 193-208.
81. Cornell, R.G. (1980) Evaluation of bioavailability data using nonparametric statistics. In Drug Absorption and Disposition: Statistical Considerations; Albert, K., ed., 51-57: American Pharmaceutical Association.
82. Cornell, R.G. (1991) Nonparametric tests of dispersion for the two period cross-over design. Commumications in Statistical Theory and Methodology, 20, 1099-1106.
83. Cox, D.R. (1967) Fieller’s theorem and a generalization. Biometrika, 54, 567-572.
84. Crowder, M.J., Kimber, A.C., Smith, R.L., Sweeting, T.J. (1991) Statistical Analysis of Reliability Data., Chapman and Hall, London.
85. Crow, E.L., Shimizu, K. (1988) Lognormal Distributions. Marcel Dekker, New York.
86. Cytel (1995) StatXact 3 for Windows: Statistical Software for Exact Nonparametric Inference (User Manual). Cytel Software Corporation, Cambridge, MA.
87. D’Angelo, G., Potvin, D., Turgeon, J. (2001) Carry-over effects in bioequivalence studies. Journal of Biopharmaceutical Statistics, 11, 27-36.
88. Davidian, M., Giltinan, D.M. (1995) Nonlinear Models for Repeated Measurement Data. Chapman and Hall, London.
89. Diletti, E., Hauschke, D., Steinijans, V.W. (1991) Sample size determination for bioequivalence assessment by means of confidence intervals. International Journal of Clinical Pharmacology, Therapeutics, and Toxicology, 29, 1-8.
90. DiMasi, J. (2001) New drug development in the USA from 1963 to 1999; Risks in new drug development - Approval success rates for investigational drugs. Clinical Pharmacology and Therapeutics, 69, 286-307.
91. Dmitrienko, A., Smith, B. (2003) Repeated-measures models in the analysis of QT-interval data. Pharmaceutical Statistics, 2, 175-190.
92. Dragalin, V., Fedorov, V. (1999a) Kullback-Liebler Distance for evaluating bioequivalence. SB BDS Technical Report 1999-03.
93. Dragalin, V., Fedorov, V. (1999b) The Total Least Squares Method in Individual Bioequivalence Evaluation. SB BDS Technical Report 1999-04.
94. Dragalin, V., Fedorov, V. (2004) Adaptive Model-Based Designs for Dose-Finding Studies. GSK BDS Technical Report 2004-02.
95. Dunnett, C.W., Gent, M. (1977) Significance testing to establish equivalence between treatments, with special reference to data in the form of 2 × 2 tables. Biometrics, 33, 593-602.
96. Efron, B., Tibshirani, R.J. (1993) An Introduction to the Bootstrap. Chapman and Hall, New York.
97. Ekbohm, E. (1981) A test for the equality of variances in the paired case with incomplete data. Biometrical Journal, 3, 261-265.
98. Ekbohm, G., Melander, H. (1989) The subject-by-formulation interaction as a criterion of interchangeability of drugs. Biometrics, 45, 1249-1254.
99. El-Tahtawy, A.A., Tozer, T.N., Harrison, F., Lesko, L., Williams, R. (1998) Evaluation of bioequivalence of highly variable drug using clinical trial simulations. II: Comparison of Single and Multiple-Dose Trials using AUC and Cmax. Pharmaceutical Research, 15, 98-104.
100. EMEA, European Agency for the Evaluation of Medicinal Products, Committee for ProprietaryMedicinal Products (2001) Guidance on the Investigation of Bioavailability and Bioequivalence. http://www.emea.eu.int/index
101. EMEA, European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (2004) Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Lipid Disorders. http://www.emea.eu.int/index
102. Endrenyi, L., Fritsch, S., Yan, W. (1991) Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 29, 394-399.
103. Endrenyi, L., Schulz, M. (1993) Individual variation and the acceptance of average bioequivalence. Drug Information Journal, 27, 195-201.
104. Endrenyi, L. (1994) A method for the evaluation of individual bioequivalence. International Journal of Clinical Pharmacology and Therapeutics, 32, 497-508.
105. Endrenyi, L., Czimadia, F., Tothfalusi, L, Chen, M.L. (1998a) Metrics comparing simulated early concentration profiles for the determination of bioequivalence. Pharmaceutical Research, 15, 1292-1299.
106. Endrenyi, L., Amidon, G.L., Midha, K.K., Skelly, J.P. (1998b) Individual bioequivalence: Attractive in principle, difficult in practice. Pharmaceutical Research, 15, 1321-1325.
107. Endrenyi, L., Hao, Y. (1998c) Assymetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 36, 1-8.
108. Endrenyi, L., Midha, K.K. (1998d) Individual bioequivalence-has its time come? European Journal of Pharmaceutical Sciences, 6, 271-277.
109. Endrenyi, L., Tothfalusi, L. (1999) Subject-by-formulation interaction in determination of individual bioequivalence: Bias and prevalence. Pharmaceutical Research, 16, 186-190.
110. Endrenyi, L., Taback, N., Tothfalusi, L. (2000) Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence. Statistics in Medicine, 19, 2867-2878.
111. Ereshefsky, L., Meyer, M. (2001) Comparison of the bioequivalence of generic versus branded Clozapine. Journal of Clinical Psychiatry, 62(Suppl 5), 3-27.
112. Esinhart, J.D., Chinchilli, V.M. (1994a) Extensions to the use of tolerance intervals for the assessment of individual bioequivalence. Journal of Biopharmaceutical Statistics, 4, 39-52.
113. Esinhart, J.D., Chinchilli, V.M. (1994b) Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals. International Journal of Clinical Pharmacology and Therapeutics, 32, 26-32.
114. FDA Guidance (1987) Guidance for In-Vivo Bioequivalence Study for Slow Release Potassium-Chloride Tablets and Capsules. http://www.fda.gov/cder/guidance
115. FDA Guidance (1989) Guidance for the In-Vitro Portion of Bioequivalence Requirements for Metaproterenol Sulfate and Albuterol Inhalation Aerosols (Metered Dose Inhalers). http://www.fda.gov/cder/guidance
116. FDA Guidance (1992) Statistical Procedures for Bioequivalence Studies Using a Standard Two Treatment Cross-over Design.
117. FDA Guidance (1993) Interim Guidance -Cholestyramine Powder In-Vitro Bioequivalence. http://www.fda.gov/cder/guidance
118. FDA Guidance (1994) Phenytoin Sodium Capsules, Tablets, and Suspension In VIvo Bioequivalence and In-Vitro Dissolution Testing. http://www.fda.gov/cder/guidance
119. FDA Guidance (1995a) Topical Dermatologic Corticosteroids: In-Vivo Bioequivalence. http://www.fda.gov/cder/guidance
120. FDA Guidance (1995b) Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterised, Therapeutic, Biotechnology-derived Products. http://www.fda.gov/cder/guidance
121. FDA Guidance (1996) Clozapine Tablets In-Vivo Bioequivalence and In-Vitro Dissolution Testing. http://www.fda.gov/cder/guidance
122. FDA Preliminary Draft Guidance (1997a) In Vivo Bioequivalence Studies Based on Population and Individual Bioequivalence Approaches.
123. FDA Guidance (1997b) Drug Metabolism, Drug Interaction Studies in the Drug Development Process: Studies In-vitro. http://www.fda.gov/cder/guidance
124. FDA Guidance (1998) Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Recommendations for Dosing and Labeling. http://www.fda.gov/cder/guidance
125. FDA Draft Guidance (1999a) BA and BE Studies for Orally Administered Drug Products: General Considerations.
126. FDA Draft Guidance (1999b) Average, Population, and Individual Approaches to Establishing Bioequivalence.
127. FDA Guidance (1999c) In-Vivo Drug Metabolism, Drug-Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling. http://www.fda.gov/cder/guidance
128. FDA Guidance (1999d) Population Pharmacokinetics. http://www.fda.gov/cder/guidance
129. FDA Guidance (2000a) Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. http://www.fda.gov/cder/guidance
130. FDA Guidance (2000b) Bioavailability and Bioequivalence Studies for Orally Administered Drug Products: General Considerations.
131. FDA Guidance (2001) Statistical Approaches to Establishing Bioequivalence. http://www.fda.gov/cder/guidance
132. FDA Guidance (2002a) Food-Effect Bioavailability and Fed Bioequivalence Studies. http://www.fda.gov/cder/guidance
133. FDA Draft Guidance (2002b) Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. http://www.fda.gov/cder/guidance
134. FDA Guidance (2003a) Exposure-Response Relationships -Study Design, Data Analysis, and Regulatory Applications. http://www.fda.gov/cder/guidance
135. FDA Guidance (2003b) Bioavailability and Bioequivalence Studies for Orally Administered Drug Products: General Considerations. http://www.fda.gov/cder/guidance
136. FDA Guidance (2003c) Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. http://www.fda.gov/cder/guidance
137. FDA Position Paper (2004a) Challenge and Opportunity on the Critical Path to New Medical Products.
138. FDA Draft Guidance (2004b) Pharmacokinetics in Pregnancy -Study Design, Data Analysis, and Impact on Dosing and Labeling. http://www.fda.gov/cder/guidance
139. Guidance for Industry (2004c) E5 - Ethnic Factors in the Acceptability of Foreign Clinical Data: Questions and Answers. http://www.fda.gov/cder/guidance
140. Federer, W.T., Raghavarao, D. (1975) On augmented designs. Biometrics, 31, 29-35.
141. Fenech, A., Harville, D. (1991) Exact confidence sets for variance components in unbalanced mixed linear models. The Annals of Statistics, 19, 1771-1785.
142. Fieller, E. (1954) Some problems in interval estimation. Journal of the Royal Statistical Society, Series B, 16, 175-185.
143. Fisher, L.D., van Belle, G. (1993) Biostatistics, A Methodology for the Health Sciences. John Wiley and Sons, New York.
144. Fleiss, J.L. (1971) On the distribution of a linear combination of independent chi squares. Journal of the American Statistical Association, 66, 142-144.
145. Fleiss, J.L. (1986) Letter to the editor: On multiperiod cross-over studies. Biometrics, 449-450.
146. Fleiss, J.L. (1989) A critique of recent research on the two treatment cross-over design. Controlled Clinical Trials, 10, 237-243.
147. Fleming, T., DeMets, D. (1996) Surrogate endpoints in clinical trials: Are we being misled?. Annals of Internal Medicine, 125, 605-613.
148. Fluehler, H., Hirtz, J., Moser, H.A. (1981) An aid to decision making in bioequivalence assessment. Journal of Pharmacokinetics and Biopharmaceutics, 9, 235-243.
149. Fridericia, L. (1920) Die systolendauer im elecktrokardiogramm bei normalen menschen und bei herzkranken. Acta Medica Scandinavia, 53, 469-486.
150. Freeman, P. (1989) The performance of the two-stage analysis of two treatment, two period cross-over trials. Statistics in Medicine, 8, 1421-1432.
151. Friedman, L., Furberg, C., DeMets, D. (1998) Fundamentals of Clinical Trials, 3ed. Springer, New York.
152. Friesen, M.H., Walker, S.E. (1999) Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model. J Pharm Pharmaceut Sci, 2, 15-22.
153. Gaffney, M. (1992) Variance components in comparative bioavailability studies. Journal of Pharmaceutical Sciences, 81, 315-317.
154. Garthwaite, P., Kadane, J., O’Hagan, A. (2005) Statistical methods for eliciting probability distributions. Journal of the American Statistical Association, 100, 680-700.
155. Geischke, R., Steimer, J.-L. (2000) Pharmacometrics: modeling and simulation tools to improve decision making in clinical drug development. European Journal of Drug Metabolism and Pharmacokinetics, 25, 49-58.
156. Gelfland, A.E., Hills, S.E., Racine-Poon, A., Smith, A.F-M. (1990a) Illustration of Bayesian inference in normal data models using Gibbs sampling. Journal of the American Statistical Association, 85, 972-985.
157. Gelfand, A.E., Smith, A.F-M. (1990b) Sampling-based approaches to calculating marginal densities. Journal of the American Statistical Association, 85, 398-409.
158. Ghosh, K., Hesney, M., Sarkar, S., Thiyagarajan, B. (1996) Comprehensive criteria for population and individual bioequivalence. Proceedings of the American Statistical Association, Biopharmaceutics Chapter, 77-81.
159. Ghosh, P., Khattree, R. (2003) Bayesian approach to average bioequivalence using Bayes’ factor. Journal of Biopharmaceutical Statistics, 13, 719-734.
160. Giesbrecht, F., Burns, J. (1985) Two-stage analysis based on a mixed model: Large sample asymptotic theory and small-sample simulation results. Biometrics, 41, 477-486.
161. Gilks, W.R., Richardson, S., Spiegelhalter, D. (1996) Markov Chain Monte Carlo in Practice, Chapman and Hall, NY.
162. Gobburu, J., Marroum, P. (2001) Utilisation of pharmacokineticpharmacodynamic modelling and simulation in regulatory decision making. Clinical Pharmacokinetics, 40, 883-892.
163. Godbillon, J., Cardot, J.B., LeCaillon, G., Sioufi, A. (1996) Bioequivalence assessment: a pharmaceutical industry perspective. European Journal of Drug Metabolism and Pharmacokinetics, 21, 153-158.
164. Goodman, S. (1994) The use of predictive confidence intervals when planning experiments and the misuse of power when interpreting results. Annals of Internal Medicine, 121, 200-206.
165. Gould, A.L. (1995) Group sequential extensions of a standard bioequivalence testing procedure. Journal of Pharmacokinetics and Biopharmaceutics, 23, 57-86.
166. Gould, A.L. (1997) Discussion of individual bioequivalence by M.L. Chen. Journal of Biopharmaceutical Statistics, 7, 23-29.
167. Gould, A.L. (2000) A practical approach for evaluating population and individual bioequivalence. Statistics in Medicine, 19, 2721-2740.
168. Grahnan, A., Hammarlund, M., Lundqvist, T. (1984) Implications of intraindividual variability in bioavailability studies of furosemide. European Journal of Clinical Pharmacology, 27, 595-602.
169. Graybill, F.A., Wang, C.H. (1980) Confidence intervals on nonnegative linear combinations of variances. Journal of the American Statistical Association, 75, 869-873.
170. Grieve, A.P. (1985) A Bayesian analysis of the two-period crossover design for clinical trials. Biometrics, 21, 467-480.
171. Grieve, A.P. (1990) Cross-over vs. Parallel Designs. In Statistical Methodology in the Pharmaceutical Sciences, Berry, D., ed., 239-270, Marcel Dekker, New York.
172. Grizzle, J.E. (1965) The two-period changeover design and its use in clinical trials. Biometrics, 21, 467-480.
173. Guilbaud, O. (1993) Exact inference about the within-subject variability in 2 × 2 cross-over studies. Journal of the American Statistical Association, 88, 939-946.
174. Guilbaud, O. (1999) Exact comparisons of means and variances in 2×2 cross-over trials. Drug Information Journal, 33, 455-469.
175. Hald, A. (1990) A History of Probability and Statistics and Their Applications before 1750. John Wiley and Sons, New York.
176. Hald, A. (1998) A History of Mathematical Statistics from 1750 to 1930. John Wiley and Sons, New York.
177. Hale, M., Gillespie, W.R., Gupta, S.K., Tuk, B., Holford, N. (1996) Clinical trial simulation. Applied Clinical Trials, 6, 35-40.
178. Hare, D., Foster, T. (1990) The Orange Book: the FDA’s advice on therapeutic equivalence. American Pharmacy, NS30, 35-37.
179. Harrell, F. (2001) Regression Modelling Strategies. Springer, New York.
180. Harville, D.A. (1976) Confidence intervals and sets for linear combinations of fixed and random effects. Biometrics, 32, 403-407.
181. Harville, D.A. (1977) Maximum likelihood approaches to variance component estimation and to related problems. Journal of the American Statistical Association, 72, 320-340.
182. Harville, D.A. (1990) BLUP (best linear unbiased prediction) and beyond. AdStMetGen, 239-276.
183. Harville, D.A., Carriquiry, A.L. (1992) Classical and Bayesian prediction as applied to an unbalanced mixed linear model. Biometrics, 48, 987-1003.
184. Harville, D.A., Jeske, D.R. (1992) Mean squared error of estimation or prediction under a general linear model. Journal of the American Statistical Association, 87, 724-731.
185. Harville, D.A., Zimmermann, A.G. (1996) The posterior distribution of the fixed and random effects in a mixed-effects linear model. Journal of Statistical Computing and Simulation, 54, 211-229.
186. Hauck, W.W., Anderson S. (1984) A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. Journal of Pharmacokinetics and Biopharmaceutics, 12, 83-91.
187. Hauck, W.W., Anderson S. (1986) A proposal for interpreting and reporting negative studies. Statistics in Medicine, 5, 203-209.
188. Hauck, W.W., Anderson S. (1992) Types of bioequivalence and related statistical considerations. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 30, 181-187.
189. Hauck, W.W., Anderson S. (1994) Measuring switchability and presciptability: when is average bioequivalence sufficient. Journal of Pharmacokinetics and Biopharmaceutics, 22, 551-564.
190. Hauck, W.W., Anderson, S. (1999) Some issues in the design and analysis of equivalence trials. Drug Information Journal, 33, 109-118.
191. Hauck, W.W., Hyslop, T., Anderson, S., Bois, F.Y., Tozer, T.N. (1995) Statistical and regulatory considerations for multiple measures in bioequivalence testing. Clinical Research and Regulatory Affairs, 12, 249-265.
192. Hauck, W.W, Chen, ML., Hyslop, T., Patnaik, P., Shuirmann, D., Williams, R., for the FDA Individual Bioequivalence Working Group. (1996) Mean differences versus variability reduction:tradeoff in aggregate measures for individual bioequivalence. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 34, 535-541.
193. Hauck, W.W., Hauschke, D., Diletti, E., Bois, F.Y., Steinijans, V.W., Anderson, S. (1997a) Choice of Student’s t or Wilcoxon based confidence intervals for assessment of bioequivalence. Journal of Biopharmaceutical Statistics, 7, 179-189.
194. Hauck, W.W, Bois, F.Y., Hyslop, T., Gee, L., Anderson, S. (1997b) A parametric approach to population bioequivalence. Statistics in Medicine, 16, 441-454.
195. Hauck, W.W., Preston, P.E., Bois, F.Y. (1997c) A group sequential approach to cross-over trials for average bioequivalence. Journal of Biopharmaceutical Statistics, 7, 87-96.
196. Hauck, W.W., Hyslop, T., Chen, M.L., Patnaik, R., Williams, R.L., and the FDA Population/Individual Bioequivalence Working Group. (2000) Subject-by-formulation interaction in bioequivalence:Conceptual and statistical issues. Pharmaceutical Research, 17, 375-380.
197. Hauck, W.W., Parekh, A., Lesko, L., Chen, M-L., Williams, R. (2001) Limits of 80%-125% for AUC and 70%-143% for Cmax - What is the impact on bioequivalence studies? International Journal of Clinical Pharmacology and Therapeutics, 39, 350-355.
198. Hauschke, D., Steinijans, V.W., Diletti, E. (1990) A distribution free procedure for the statistical analysis of bioequivalence studies. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 28, 72-78.
199. Hauschke, D., Hothorn, L. (1998) Safety assessment in toxicological studies: Proof of safety versus proof of hazard. In Design and Analysis of Animal Studies in Pharmaceutical Development, Chow, S., and Liu, J., eds., 197-226, Marcel Dekker, New York.
200. Hauschke, D., Steinijans, V.W. (2000) The US draft guidance regarding population and individual bioequivalence approaches:Comments by a research-based pharmaceutical company. Statistics in Medicine, 19, 2769-2774.
201. Hauschke, D. (2002) Letter to the Editor and Correspondence on ‘A Note on Sample Size Calculation in Bioequivalence Trials’ by Chow and Wang (2001;28:155-169). Journal of Pharmacokinetics and Pharmacodynamics, 29, 89-102.
202. Haynes, J.D. (1981) Statistical simulation study of new proposed uniformity requirement for bioequivalency studies. Journal of Pharmaceutical Sciences, 70, 673-675.
203. Hellriegel, E.T., Bjornsson, T.D., Hauck, W.W. (1996) Interpatient variability in bioavailability is related to the extent of absorption:implications for bioavailability and bioequivalence studies. Clinical Pharmacology and Therapeutics, 60, 601-607.
204. Herchuelz, A. (1996) Bioequivalence assessment and the conduct of bioequivalence trials: a European point of view. European Journal of Drug Metabolism and Pharmacokinetics, 21, 149-152.
205. Hills, M., Armitage, P. (1979) The two period cross-over trial. British Journal of Clinical Pharmacology, 8, 7-20.
206. Hinkelmann, K., Kempthorne, O. (1994) Design and Analysis of Experiments, Volume I: Introduction to Experimental Design, John Wiley and Sons, New York.
207. Hodges, J., Lehman, E. (1963) Estimates of location based on rank tests. Annals of Mathematical Statistics, 34, 598-611.
208. Hoenig, J., Heisey, D. (2001) The abuse of power: The pervasive fallacy of power calculations for data analysis. The American Statistician, 55, 19-24.
209. Holder, D., Hsuan, F. (1993a) Moment based criteria for determining bioequivalence. Biometrika, 80, 835-846.
210. Holder, D., Hsuan, F. (1993b) A moment based criteria for determining individual bioequivalence. Drug Information Journal, 29, 965-979.
211. Holford, N.H.G., Hale, M., Ko, H.C., Steimer, J.-L., Sheiner, L.B., Peck, C.C. (1999) Simulation in drug development:good practices. Center for Drug Development Science, www.dml.georgetown.edu/cdds
212. Hollander, M., Wolfe, D. (1999) Nonparametric Statistical Methods.John Wiley and Sons, New York.
213. Honig, P., Woosley, R., Zamani, K., Conner, D., Cantilena, L. (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clinical Pharmacology and Therapeutics, 52, 231-238.
214. Howe, W.G. (1974) Approximate confidence limits on the mean of X+Y where X and Y are two tabled independent random variables. Journal of the American Statistical Association, 69, 789-794.
215. Hsu, J.C., Hwang, J.-T.G., Liu, H-K., Ruberg, S.J. (1994) Confidence limits associated with tests for bioequivalence. Biometrika, 81, 103-114.
216. Huitson, A. (1955) A method for assigning confidence limits to linear combinations of variances. Biometrika, 42, 471-479.
217. Hunt, M.I. (2000) Prescription Drugs and Intellectual Property Protection. National Institute for Health Care Management:Foundation Issue Brief.
218. Huque, M.F., Dubey, S., Fredd, S. (1989) Establishing therapeutic equivalence with clinical endpoints. Proceedings of the American Statistical Association, Biopharmaceutics Chapter, 46-52.
219. Huynh, H., Feldt, L.S. (1970) Conditions under which mean square ratios in repeated measures designs have exact Fdistributions. Journal of the American Statistical Association, 65, 1582-1589.
220. Hwang, J.S. (1996) Numerical solutions for a sequential approach to bioequivalence. Statistica Sinica, 6, 663-673.
221. Hwang, J.T.G., Wang, W. (1997) The validity of the test of individual equivalence ratios. Biometrika, 84, 893-900.
222. Hwang, S., Huber, P.B., Hesney, M., Kwan, K.C. (1978) Bioequivalence and interchangeabiliy. Journal of Pharmaceutical Sciences, 67, IV.
223. Hyslop, T., Hsuan, F., Holder, D.J. (2000) A small sample confidence interval approach to assess individual bioequivalence. Statistics in Medicine, 19, 2885-2897.
224. Hyslop, T., Inglewicz, B. (2001) Alternative cross-over designs for individual bioequivalence. Proceedings of the Annual Meeting of the American Statisticial Association.
225. International Conference on Harmonization (1994) Dose Response Information to Support Drug Registration. http://www.fda.gov/cder/guidance
226. International Conference on Harmonization (1995) Text on Validation of Analytical Procedures. http://www.fda.gov/cder/guidance
227. International Conference on Harmonization (1998) Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data. http://www.fda.gov/cder/guidance
228. International Conference on Harmonization (1998) Statistical Principles for Clinical Trials. http://www.fda.gov/cder/guidance
229. International Conference on Harmonization Consensus Guideline, Step 4 (2005) The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrythmic Potential for Non-Antiarrythmic Drugs. http://www.fda.gov/cder/guidance
230. Jackson, A. (2000) The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and firstpass effect. Pharmaceutical Research, 17, 1432-1436.
231. Jackson, A., Robbie, G., Marroum, P. (2004) Metabolites and bioequivalence - past and present. Clinical Pharmacokinetics, 43, 655-672.
232. Japan MHW (1997) Guideline for Bioequivalence Studies of Generic Products.
233. Jennison, C., Turnbull, B.W. (2000) Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall, New York.
234. Jennrich, R.I., Schluchter, M.D. (1986) Unbalanced repeatedmeasures models with structured covariance matrices. Biometrics, 42, 805-820.
235. Johnson, N.L., Kotz, S., Balakrishnan, N. (1994) Continuous Univariate Distributions, Vols. 1 and 2. John Wiley and Sons, New York.
236. Johnston, A., Belitsky, P., Frei, U., Horvath, J., Hoyer, P., Helderman, J., Oellerich, M., Pollard, S., Riad, H., Rigotti, P., Keown, P., Nashan, B. (2004) Potential clinical implications of substitution of generic formulations for cyclosporine microemulsion (Neoral) in transplant recipients. European Journal of Clinical Pharmacology, 60, 389-395.
237. Jones, B., Kenward M.G. (2003) Design and Analysis of Crossover Trials, 2ed. Chapman and Hall, London.
238. Jones, B., Jarvis, P., Lewis, J.A., Ebbutt, A.F. (1996) Trials to assess equivalence: The importance of rigourous methods. British Medical Journal, 313, 36-39.
239. Jones, B., Lane, P.W. (2004). Procedure XOEFFICIENCY (Calculates efficiency of effects in cross-over designs). GenStat Release 7.1 Reference Manual, Part 3: Procedure Library PL15, VSN International, Oxford.
240. Jones, B., Deppe, C. (2000) Recent developments in the design of cross-over trials: A brief review and bibliography. Proceedings of the Conference on Recent Developments in the Design of Experiments and Related Topics.
241. Julious, S., Debarnot, C. A.-M. (2000) Why are pharmacokinetic data summarized by arithmetic means? Journal of Biopharmaceutical Statistics, 10, 55-71.
242. Julious, S., Patterson, S. (2004) Sample sizes for estimation in clinical research. Pharmaceutical Statistics, 3, 213-215.
243. Kanfer, F.-H.J., Geertsema, J.C., Steyn, H.S. (1988) A Two-Stage Procedure for Testing Bioequivalence. Proceedings of the American Statistical Association, 148-152.
244. Kawai, N., Andoh, M., Uwoi, T., Goto, M. (2000) Statistical approaches to accepting foreign clinical data. Drug Information Journal, 34, 1265-1272.
245. Keiser, M., Hauschke, D. (2005) Assessment of clinical relevance by considering point estimates and associated confidence intervals. Pharmaceutical Statistics, 4, 101-107.
246. Kenward, M., Roger, J. (1997) Small sample inference for fixed effects from restricted maximum likelihood. Biometrics, 33, 983-997.
247. Kepner, J.L., Randles, R.H. (1982) Detecting unequal marginal scales in a bi-variate population. Journal of the American Statistical Association, 77, 475-482.
248. Kershner, R.P., Federer, W.T. (1981) Two treatment cross-over designs for estimating a variety of effects. Journal of the American Statistical Association, 76, 612-619.
249. Kimanani, E.K., Potvin, D. (1997) A parametric confidence interval for a moment based scaled criterion for individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 25, 595-614.
250. Kimanani, E.K., Lavigne, J., Potvin, D. (2000a) Numerical methods for the evaluation of individual bioequivalence. Statistics in Medicine, 19, 2775-2795.
251. Kimanani, E., Stypinski, D., Curtis, G., Stiles, M., Heessels, P., Logan, S., Melson, K., St Germain, E., Boswell, G. (2000b) A contract research organization’s response to the new FDA guidances for bioequivalence/bioavailability studies for orally administered drug products. Journal of Clinical Pharmacology, 40, 1102-1108.
252. Kirkwood, T-B.L., Westlake, T.J. (1981) Letter to the editor and response. Biometrics, 37, 589-593.
253. Koch, G. (1972) The use of non-parametric methods in the statistical analysis of the two-period changeover design. Biometrics, 28, 577-584.
254. Kong, L., Koch, G., Liu, T., Wang, H. (2004) Performance of some multiple testing procedures to compare three doses of a test drug and placebo. Pharmaceutical Statistics, 4, 25-35.
255. Kullback, S. (1968) Information Theory and Statistics. Dover Publications, New York.
256. Lacey, L.F., Keene, O.N., Bye, A. (1995) Glaxo’s expreience of different absorption rate metrics of immediate release and extended release dosage forms. Drug Information Journal, 29, 821-840.
257. Lacey, L.F., Keene, O.N., Pritchard, J.F., Bye, A. (1997) Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? Journal of Biopharmaceutical Statistics, 7, 171-178.
258. Lachenbruch, P. (2003) Proper metrics for clinical trials: transformations and other procedures to remove non-normality effects. Statistics in Medicine, 22, 3823-3842.
259. Laird, N.M., Ware, J.H. (1982) Random effects models for longitudinal data. Biometrics, 38, 963-974.
260. Lee, Y., Shao, J., Chow, S-C., Wang, H. (2002) Tests for intersubject and total variabilities under cross-over designs. Journal of Biopharmaceutical Statistics, 12(4), 503-534.
261. Lehmann, E.L. (1975). Nonparametrics: Statistical Methods Based on Ranks. Holden-Day, San Francisco.
262. Lesko, L., Rowland, M., Peck, C., Blaschke, T. (2000) Optimizing the Science of Drug Development: opportunities for better candidate selection and accelerated evaluation in humans. European Journal of Pharmaceutical Sciences, 10, iv-xiv.
263. Lesko, L., Atkinson, A. (2001) Use of biomarkers and surrogate markers in drug development. Annu. Rev. Pharmacol. Toxicol., 41, 347-66.
264. Levy, G. (1995) The clay feet of bioequivalence testing. Journal of Pharmacy and Pharmacology, 47, 975-977.
265. Littell, R.C., Milliken, G.A., Stroup, W.W., Wolfinger, R.D. (1996) SAS System for Mixed Models. SAS Institute, Cary, North Carolina.
266. Lin, L. (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics, 45, 255-268.
267. Lin, L. (1992) Assay validation using the concordance correlation coefficient. Biometrics, 48, 599-604.
268. Lin, L. (2000) Total deviation index for measuring individual agreement with applications in laboratory performance and bioequivalence. Statistics in Medicine, 19, 255-270.
269. Lindley, D.V. (1971) Making Decisions, 2ed. John Wiley and Sons, New York.
270. Lindley, D.V, Singpurwalla, N.D. (1991) On the evidence needed to reach agreed action between adversaries, with application to acceptance sampling. Journal of the American Statistical Association, 86, 933-937.
271. Lindley, D.V. (1997) The choice of sample size (with discussion). The Statistician, 46, 129-166.
272. Lindley, D.V. (1998) Decision analysis and bioequivalence trials. Statistical Science, 13, 136-141.
273. Lindsey, J.K. (1996) Parametric Statistical Inference. Clarendon Press, Oxford.
274. Lindsey, J.K. (2001) Nonlinear Models in Medical Statistics. Oxford University Press, Oxford.
275. Lindsey, J.K., Jones, B. (1997) Treatment-patient interactions for diagnostics of cross-over trials. Statistics in Medicine, 16, 1955-1964.
276. Lindsey, J.K., Wang, J., Byrom, W.D., Jones, B. (1999) Modeling the covariance structure in pharmacokinetic cross-over trials. Journal of Biopharmaceutical Statistics, 9, 439-450.
277. Lindstrom, M.J., Bates, D.M. (1988) Newton-Raphson and EM algorithms for linear mixed-effects models and repeated-measures data. Journal of the American Statisticial Association, 83, 1014-1022.
278. Liu, J.-P., Chow, S-C. (2002a) Bridging studies in clinical development. Journal of Biopharmaceutical Statistics, 12, 359-367.
279. Liu, J.-P., Hsiao, C-F., Hsueh, H. (2002b) Bayesian approach to evaluation of bridging studies. Journal of Biopharmaceutical Statistics, 12, 401-408.
280. Liu, J-P., Hsueh, H., Hsiao, C-F. (2004) A Bayesian noninferiority approach to evaluation of bridging studies. Journal of Biopharmaceutical Statistics, 14, 291-300.
281. Locke, C.S. (1984) An exact confidence interval for untransformed data for the ratio of two formulation means. Journal of Pharmacokinetics and Biopharmaceutics, 12, 649-655.
282. Longford, N.T. (1999) Selection bias and treatment heterogeneity in clinical trials. Statistics in Medicine, 18, 1467-1474.
283. Longford, N.T. (2000) An alternative definition of individual bioequivalence. Statistica Neerlandica, 14, 14-36.
284. Lu, T.C., Graybill, F.A., Burdick, R.K. (1988) Confidence intervals on a difference of expected mean squares. Journal of Statistical Planning and Inference, 18, 35-43.
285. Lund, R.E. (1975) Tables for an approximate test for outliers in linear models. Technometrics, 17, 473-476.
286. Machado, S., Miller, R., Hu, C. (1999) A regulatory perspective on pharmacokinetic and pharmacodynamic modelling. Statistical Methods in Medical Research, 8, 217-245.
287. Mallet, A. (1986) A maximum likelihood estimation method for random coefficient regression models. Biometrika, 73, 645-656.
288. Mancinelli, L., Frassetto, L., Floren, L., Dressler, D., Carrier, S., Bekersky, I., Benet, L., Christians, U. (2001) The pharmacokinetics and metabolic disposition of Tacrolimus: A comparison across ethnic groups. Clinical Pharmacology and Therapeutics, 69, 24-31.
289. Mandallaz, D., Mau, J. (1981) Comparison of different methods for decison making in bioequivalence assessment. Biometrics, 37, 213-222.
290. Marcus, R., Peritz, E., Gabriel, K.R. (1976) On closed testing procedures with special reference to ordered analysis of variance. Biometrika, 63, 655-60.
291. Marston, S.A., Polli, J.E. (1997) Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence. Pharmaceutical Research, 14, 1363-1369.
292. Marzo, A., Monti, N.C., Tettamanti, R.A., Crivelli, F., Bo, L.D., Mazzucchelli, P., Meoli, A., Pezzuto, D., Corsico, A. (2000) Bioequivalence of inhaled Formoterol Fumurate assessed from pharmacodynamic, safety, and urinary pharmacokinetic data. Arzneim-Forsch./Drug Res., 50, 559-563.
293. Matthews, J. (1994) Modelling and optimality in the design of cross-over studies for medical applications. Journal of Statistical Planning and Inference, 42, 89-108.
294. Mauger, D.T., Chinchilli, V.M. (2000) An alternative index for assessing profile similarity in bioequivalence trials. Statistics in Medicine, 19, 2855-2866.
295. McCulloch, C.E. (1987) Tests for equality of variances with paired data. Communications in Statistical Theory and Methods, 16, 1377-1391.
296. Meibohm, B., Derendorf, H. (2002) Pharmacokineticpharmacodynamic studies in drug product development. Journal of Pharmaceutical Sciences, 91, 18-31.
297. Metzler, C.M. (1974) Bioavailability: A problem in equivalence. Biometrics, 30, 309-317.
298. Metzler, C.M., Huang, D.C. (1983) Statistical methods for bioavailability and bioequivalence. Clinical Research Practices and Drug Regulatory Affairs, 1, 109-132.
299. Meyer, M.C. (1995) Current scientific issues regarding bioavailability/ bioequivalence studies: An academic view. Drug Information Journal, 29, 805-812.
300. Meyer, M.C., Straughn, A.B., Jarvi, E.J., Patrick, K.S., Pelsor, F.R., Williams, R.L., Patnaik, R., Chen, M.L., Shah, V.P. (2000) Bioequivalence of Methylphenidate immediate-release tablets using a replicated study design to characterize intra-subject variability. Pharmaceutical Research, 17, 381-384.
301. Meyer, M.C., Straughn, A.B., Mhatre, R.M., Shah, V.P., Chen, M.-L., Williams, R.L., Lesko, L.J. (2001) Variability in the bioavailability of Phenytoin capsules in males and females. Pharmaceutical Research, 18, 394-397.
302. Midha, K.K., Ormsby, E.D., Hubbard, J.W., McKay, G., Hawes, E.M., Gavalas, L., McGilveray, I.J. (1993) Logarithmic transformation in bioequivalence: Application with two formulations of Perphenazine. Journal of Pharmaceutical Sciences, 82, 138-144.
303. Midha, K.K., Rawson, M.J., Hubbard, J.W. (1997a) Individual and average bioequivalence of high variability drugs and drug products. Journal of Pharmaceutical Sciences, 86, 1193-1197.
304. Midha, K.K., Rawson, M.J., Hubbard, J.W. (1997b) Bioequivalence:switchability and scaling. European Journal of Pharmaceutical Sciences, 6, 87-91.
305. Millard, S.P., Krause, A. (2001) Applied Statistics in the Pharmaceutical Industry. Springer, New York.
306. Miller, M. (2001) Gender-based differences in the toxicity of pharmaceuticals - The Food and Drug Administration’s perspective. International Journal of Toxicology, 20, 149-152.
307. Milliken, G.A., Johnson, D.E. (1992) Analysis of Messy Data, Vol 1: Designed Experiments. Chapman and Hall, New York.
308. Morgan, W.A. (1939) A test for the significance of the difference between two variances in a sample from a bi-variate normal population. Biometrika, 31, 13-19.
309. Morrison, D. (1990) Multivariate Statistical Methods, 3ed. Mc-Graw Hill, New York.
310. Moss, A. (1993) Measurement of the QT interval and the risk associated with QT interval prolongation. American Journal of Cardiology, 72, 23B-25B.
311. Muirhead, R.J. (1982) Aspects of Multivariate Statistical Theory. John Wiley and Sons, New York.
312. Munk, A. (1993) An improvement on commonly used tests in bioequivalence assessment. Biometrics, 49, 1225-1230.
313. Munk, A., Pfluger, R. (1999) 1-_ equivalence confidence rules for convex alternatives are _/2 tests with applications to the multivariate assessment of bioequivalence. Journal of the American Statistical Association, 94, 1311-1319.
314. Myers, R.H. (1990) Classical and Modern Regression with Applications, 2ed. PWS-Kent, Boston.
315. Nagata, R., Fukase, H., Rafizadeh-Kabe, J. (2000) East-West development:Understanding the usability and acceptance of foreign data in Japan. International Journal of Clinical Pharmacology and Therapeutics, 38, 87-92.
316. Naito, C. (1998a) Relevance of ethnic factors in global development:Historic overview. In Proceedings of the Fourth International Conference on Harmonisation, D’Arcy, PF., Harron, D. eds., Greystone Books.
317. Naito, C. (1998b) Ethnic factors in the acceptability of foreign clinical data. Drug Information Journal, 32, 1283S-1292S.
318. Ormsby, E.D. (1999) Invited Presentation: Individual Bioequivalence:A Canadian Perspective. AAPS International Workshop on Individual Bioequivalence: Realities and Implementation.
319. O’Quigley, J., Baudoin, C. (1988) General approaches to the problem of bioequivalence. The Statistician, 37, 51-58.
320. O’Quigley, J., Pepe, M., Fisher, L. (1990) Continual reassessment method: A practical design for phase 1 studies in cancer. Biometrics, 46, 33-48.
321. Owen, D.B. (1965) A special case of a bi-variate non-central tdistribution. Biometrika, 52, 437-446.
322. Pabst, G., Jaeger, H. (1990) Review of methods and criteria for the evaluation of bioequivalence studies. European Journal of Clinical Pharmacology, 38, 5-10.
323. Patnaik, P.B. (1949) The non-central _2 and F-distributions and their applications. Biometrika, 36, 202-232.
324. Patnaik, R., Lesko, L.J., Chan, K., Williams, R.L. (1996) Bioequivalence assessment of generic drugs: An American point of view. European Journal of Drug Metabolism and Pharmacokinetics, 21, 159-164.
325. Patnaik, R.N., Lesko, L.J., Chen, ML., Williams, R.J., and the FDA Individual Bioequivalence Working Group. (1997) Individual bioequivalence-new concepts in the statistical assessment of bioequivalence metrics. Clinical Pharmacokinetics, 33, 1-6.
326. Patterson, H.D. (1950) The construction of balanced designs for experiments involving sequences of treatments. Biometrika, 39, 32.
327. Patterson, H.D., Thompson, R. (1971) Recovery of inter-block information when block sizes are unequal. Biometrika, 58, 545-554.
328. Patterson, S., Francis, S., Ireson, M., Webber, D., Whitehead, J. (1999) A novel Bayesian decision procedure for early-phase dose-finding studies. Journal of Biopharmaceutical Statistics, 9, 583-598.
329. Patterson, S. (2001a) A review of the development of biostatistical design and analysis techniques for assessing in vivo bioequivalence, Part 1. Indian Journal of Pharmaceutical Sciences, 63, 81-100.
330. Patterson, S. (2001b) A review of the development of biostatistical design and analysis techniques for assessing in vivo bioequivalence, Part 2. Indian Journal of Pharmaceutical Sciences, 63, 169-186.
331. Patterson, S., Zariffa, N., Howland, K., Montague, T. (2001c) Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products. European Journal of Clinical Pharmacology, 57, 663-670.
332. Patterson, S., Jones, B. (2002a) Bioequivalence and the pharmaceutical industry. Pharmaceutical Statistics, 1, 83-95.
333. Patterson, S., Jones, B. (2002b) Statistical aspects of bioequivalence in the pharmaceutical industry. Proceedings of the American Statistical Association Joint Statistical Meetings.
334. Patterson, S., Jones, B. (2002c) Clinical development planning and the use of pharmacokinetic data in ICH-E5 bridging assessments. GSK BDS Technical Report 2002-04.
335. Patterson, S., Jones, B. (2004a) Simulation assessments of statistical aspects of bioequivalence in the pharmaceutical industry. Pharmaceutical Statistics, 3, 13-23.
336. Patterson, S., Agin, M., Anziano, R., Chuang-Stein, C., Dmitrienko, A., Ferber, G., Francom, S., Geraldes, M., Ghosh, K., Mills, T., Menton, R., Natarajan, J., Offen, W., Saoud, J., Smith, B., Suresh, R., Zariffa, N. (In Press) Investigating Drug Induced QT and QTc Prolongation in the Clinic: Statistical Design and Analysis Considerations. Drug Information Journal.
337. Peace, K.E. (1986) Estimating the degree of equivalence and nonequivalence, an alternative to bioequivalence testing. Proceedings of the American Statistical Association, 63-69.
338. Peace, K., ed. (1992) Biopharmaceutical Sequential Statistical Applications. Dekker, New York.
339. Peace, K.E. (1993) Design and analysis considerations for safety data, particularly adverse events. In Drug Safety Assessment in Clinical Trials, Gibert, G.S. ed., 305-316. Marcel Dekker, New York.
340. Peck, C., Desjardins, R. (1996) Simulation of clinical trials: Encouragements and cautions. Applied Clinical Trials, 30-32.
341. Phillips, K.F. (1990) Power of the two one-sided testing procedure in bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 18, 137-144.
342. Pitman, E.C.G. (1939) A note on normal correlation. Biometrika, 31, 9-12.
343. Pocock, S.J. (1977) Group sequential methods in the design and analysis of clinical trials. Biometrics, 64, 191-199.
344. Pound, N.J. (1999) Bioavailability and Bioequivalence: Update on Guidances from TPP. AAPS International Workshop on Individual Bioequivalence: Realities and Implementation.
345. Pradhan, R.S. (1997) Role of interoccasion variation in estimation of bioequivalence: A Bayesian approach. Clinical Pharmacology and Therapeutics, 61, 186.
346. Pratt, C., Hertz, R., Elis, B., Crowell, S., Louv, W., Moye, L. (1994) Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with other over the counter antihistamines. American Journal of Cardiology, 73, 346-352.
347. Pratt, C., Ruberg, S., Morganroth, J., McNutt, B., Woodward, J., Harris, S., Ruskin, J., Moye, L. (1996) Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing drug effect from spontaneous variability. American Heart Journal, 131, 472-480.
348. Prentice, R. (1989) Surrogate endpoints in clinical trials: Definition and operational criteria. Statistics in Medicine, 8, 431-440.
349. Priori, S., Schwartz, P., Napolitano, C., Bloise, R., Ronchetti, E., Grillo, M., Vicentini, A., Spazzolini, C., Nastoli, J., Bottelli, G., Folli, R., Capelletti, D. (2003) Risk stratification in the long-QT syndrome. New England Journal of Medicine, 348, 1866-1874.
350. Quiroz, J., Ting, N., Wei, G., Burdick, R. (2002) Alternative confidence intervals for the assessment of bioequivalence in fourperiod cross-over designs. Statistics in Medicine, 21, 1825-1847.
351. Racine-Poon, A., Grieve, A.P., Fluhler, H., Smith, A. F-M. (1986) Bayesian methods in practice, experiences in the pharmaceutical industry (with discussion). Applied Statistics, 35, 93-150.
352. Racine-Poon, A., Grieve, A.P., Fluhler, H., Smith, A. F-M. (1987) A two-stage procedure for bioequivalence studies. Biometrics, 43, 847-856.
353. Racoosin, J. (2003) The clinical evaluation of QT interval prolongation and proarrythmic potential for non-antiarrythmic Drugs. Presentation at Drug Information Agency/FDA Workshop, www.diahome.org
354. Rao, C.R. (1973) Linear Statistical Inference and Its Applications, 2ed. John Wiley and Sons, New York.
355. Reigner, B., Williams, P., Patel, I., Steimer, J., Peck, C., Brummelen, P. (1997) An evaluation of the integration of pharmacokinetic and pharmacodynmaic principles in clinical drug development. Clinical Pharmacokinetics, 33, 142-152.
356. Reigner, B., Blesch, K. (2001) Estimating the starting dose for entry into humans: principles and practice. European Journal of Clinical Pharmacology, 57, 835-845.
357. Reiser, B., Guttman, I. (1986) Statistical inference for Pr(Y < X). Technometrics, 28, 253-257.
358. Rescigno, A. (1992) Bioequivalence. Pharmaceutical Research, 9, 925-928.
359. Rescigno, A., Powers, J.D. (1998) AUC and Cmax are not sufficient to prove bioequivalence. Pharmacological Research, 37, 93-95.
360. Rheinstein, P.H. (1990) Therapeutic inequivalence. Drug Safety 5, Suppl 1, 114-119.
361. Rhodes, C.T. (1997) Acceptance limits for bioequivalence studies. Clinical Research and Regulatory Affairs, 14, 127-137.
362. Ring, A., Tothfalusi, L., Endrenyi, L., Weiss, M. (2000) Sensitivity of empirical metrics of rate of absorption in bioequivalence studies. Pharmaceutical Research, 17, 583-588.
363. Rocke, D.M. (1984) On testing for bioequivalence. Biometrics, 40, 225-230.
364. Rodda, B.E., Davis R.L. (1980) Determining the probability of an important difference in bioavailability. Clinical Pharmacology and Therapeutics, 28, 247-252.
365. Roe, D., Vonesh, E., Wolfinger, R., Mensil, F., Mallet, A. (1997) Comparison of population pharmacokinetic modelling methods using simulated data: Results from the Population Modelling Workgroup. Statistics in Medicine, 16, 1241-1262.
366. Rowland, M., Tozer, T.N. (1980) Clinical Pharmacokinetics: Concepts and Applications. Lea and Febidger, Philadelphia.
367. Sarkar, S., Watts, S., Ohashi, O., Carroll, R., Uesaka, H., Mason, T., Rivera, C. (2002) Bridging data between two ethnic populations. A new application of matched case-control methodology. Drug Information Journal, 36, 349-356.
368. Statistical Analysis Software, SAS/STAT User’s Guide, Version 8. (1999). SAS Institute, Cary, NC.
369. Satterthwaite, F. (1941) Synthesis of variance. Psychometrika, 6, 309-316.
370. Schall, R. (1995) Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar. Biometrics, 51, 615-626.
371. Schall, R., Luus, H.G. (1993) On population and individual bioequivalence. Statistics in Medicine, 12, 1109-1124.
372. Schall, R., Williams, R.L. (1996) Towards a practical strategy for assessing individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 24, 133-149.
373. Schwarz, G. (1978) Estimating the dimension of a model. The Annals of Statistics, 6(2), 461-464.
374. Schuirmann, D.J. (1981) On hypothesis testing to determine if the mean of a normal distribution is contained in a known interval. Biometrics, 37, 617.
375. Schuirmann, D.J. (1987) A comparison of the two one sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15, 657-680.
376. Schuirmann, D.J. (1990) Design of bioavailability and bioequivalence studies. Drug Information Journal, 24, 315-323.
377. Schulman, R.L. (1992) Statistics in Plain English with Computer Applications. Van Nostrand Reinhold, New York.
378. Schumaker, R.C., Metzler, C.M. (1998) The phenytoin trial is a case study of individual bioequivalence. Drug Information Journal, 32, 1063-1072.
379. Searle, S.R. (1971) Linear Models. John Wiley and Sons, New York.
380. Seber, G.A. (1977) Linear Regression Analysis. John Wiley and Sons, New York.
381. Selwyn, M.R., Dempster, A.P., Hall, N.R. (1981) A Bayesian approach to bioequivalence for the 2 × 2 cross-over design. Biometrics, 37, 11-21.
382. Selwyn, M.R., Hall, N.R. (1984) On Bayesian methods for bioequivalence. Biometrics, 40, 1103-1108.
383. Senn, S. (1996) The AB/BA cross-over: How to perform the twostage analysis if you can’t be persuaded you shouldn’t. In Liber Amicorum Roel van Strik, Hansen, B., and de Ridder, M. eds., 93-100. Erasmus University, Rotterdam.
384. Senn, S. (1997) Statistical Issues in Drug Development. John Wiley and Sons, New York.
385. Senn, S. (1998) In the blood: Proposed new requirements for registering generic drugs. The Lancet, 352, 85-86.
386. Senn, S. (2000) Decisions and Bioequivalence. Conference Proceedings of Challenging Statistical Issues in Clinical Trials.
387. Senn, S. (2001) Statistical issues in bioequivalence. Statistics in Medicine, 20, 2785-2799.
388. Senn, S. (2002) Cross-over Trials in Clinical Research, 2ed. John Wiley and Sons, New York.
389. Senn, S., Lee, S. (2004a) The analysis of the AB/BA cross-over trial in the medical literature. Pharmaceutical Statistics, 3, 123-131.
390. Senn, S., D’Angelo, G., Potvin, D. (2004b) Carry-over in crossover trials in bioequivalence: Theoretical concerns and empirical evidence. Pharmaceutical Statistics, 3, 133-142.
391. Serfling, R. (1980) Approximation Theorems of Mathematical Statistics. John Wiley and Sons, New York.
392. Shaffer, J. (1986) Modified Sequentially Rejective Multiple Test Procedures. Journal of the American Statistical Association, 81, 826-831.
393. Shah, V.P., Yacobi, A., Barr, W., Benet, L.Z., Breimer, D., Dobrinska, M.R., Endrenyi, L., Fairweather, W., Gillespie, W., Gonzalez, M.A., Hooper, J., Jackson, A., Lesko, L.J., Midha, K.K., Noonan, P.K., Patnaik, R., Williams, R.L. (1996) Workshop report:Evaluation of orally administered highly variable drugs and drug formulations. Pharmaceutical Research, 13, 1590-1594.
394. Shao, J., Tu, D. (1996) The Jackknife and Bootstrap. Springer, New York.
395. Shao, J., Chow, S.-C., Wang, B. (2000a) The bootstrap procedure in individual bioequivalence. Statistics in Medicine, 19, 2741-2754.
396. Shao, J., Kubler, J., Pigeot, I. (2000b) Consistency of the bootstrap procedure in individual bioequivalence. Biometrika, 87, 573-585.
397. Shapiro, S., Wilk, M. (1965). An analysis of variance test for normality (complete samples). Biometrika, 52, 591-611.
398. Sharma, A., Pilote, S., Belanger, P., Arsenault, M., Hamelin, B. (2004). A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: A pilot study, British Journal of Clinical Pharmacology, 58, 288-297.
399. Sheiner L.B., Beal, S.L., Sambol, N.C. (1989) Study designs for dose-ranging. Clinical Pharmacology and Therapeutics, 46, 63-77.
400. Sheiner, L.B., Hashimoto, Y., Beal, S. (1991) A simulation study comparing designs for dose ranging. Statistics in Medicine, 10, 303-321.
401. Sheiner, L.B. (1992) Bioequivalence revisited. Statistics in Medicine, 11, 1777-1788.
402. Sheiner, L.B. (1997) Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics, 61, 275-291.
403. Sheiner, L.B., Steimer, J-L. (2000) Pharmacokinetic-Pharmacodynamic Modeling in Drug Development. Annu. Rev. Pharmacol. Toxicol., 40, 67-95.
404. Shih, W. (2001) Clinical trials for drug registrations in Asian-Pacific countries: Proposal for a new paradigm from a statistical perspective. Controlled Clinical Trials, 22, 357-366.
405. Singh, G.J.-P., Adams, W.P., Lesko, L.J., Shah, V.P., Molzon, J.A., Williams, R.L., Pershing, L.K. (1999) Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clinical Pharmacology and Therapeutics, 66, 346-357.
406. Smith, B., Vandenhende, F., DeSante, K., Farid, N., Welch, P., Callaghan, J., Forgue, S. (2000) Confidence interval criteria for assessment of dose proportionality. Pharmaceutical Research, 17, 1278-1283.
407. Smith, M. (2003) Software for non-linear mixed effects modelling:a review of several packages. Pharmaceutical Statistics, 2, 69-75.
408. Smith, B. (2004) Assessment of Dose Proportionality. In Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, Volume 1, Bonate, P., Howard, D., eds., 363-382. AAPS Press, USA.
409. Snikeris, F., Tingey, H.B. (1994) A two step method for assessing bioequivalence. Drug Information Journal, 28, 709-722.
410. Spino, M., Tsang, Y.C., Pop, R. (2000) Dissolution and in vivo evidence of differences in reference products: Impact on development of generic drugs. European Journal of Drug Metabolism and Pharmacokinetics, 25, 18-24.
411. Sprecher, D., Watkins, T., Behar, S., Brown, W., Rubins, H., Schaefer, E. (2003) Importance of high density lipoprotein cholesterol and triglyceride levels in coronary heart disease. The American Journal of Cardiology, 91, 575-580.
412. Srinivasan, R, Langenberg, P. (1986) A two-stage procedure with controlled error probabilities for testing equivalence. Biometrical Journal, 7, 825-833.
413. Stedman’s Medical Dictionary, 25th ed. (1990) William and Wilkins, Baltimore.
414. Steinijans, V.W., Diletti, E. (1983) Statistical analysis of bioavailability studies: Parametric and nonparametric confidence interval. European Journal of Clinical Pharmacology, 24, 127-136.
415. Steinijans, V.W., Hauschke, V. (1990) Update on the statistical analysis of bioequivalence studies. International Journal of Clinicial Pharmacology, Therapy, and Toxicology, 28, 105-110.
416. Steinijans, V.W., Hartmann, M., Huber, R., Radtke, H.W. (1991) Lack of pharmacokinetic interaction as an equivalence problem. International Journal of Clinicial Pharmacology, Therapy, and Toxicology, 29, 323-328.
417. Steinijans, V.W., Sauter, R., Hauschke, D., Elze, M. (1995) Metrics to characterize concentration-time profiles in single and multiple-dose bioequivalence studies. Drug Information Journal, 29, 981-987.
418. Steinijans, V.W., Hauschke, D., Schall, R. (1995) International harmonization of regulatory requirements for average bioequivalence and current issues in individual bioequivalence. Drug Information Journal, 29, 1055-1062.
419. Steinjans, V.W., Diletti, E. (1997) Individual bioequivalence: A European perspective. Journal of Biopharmaceutical Statistics, 7, 31-34.
420. Stokes, M., Davis, C., Koch, G. (2002) Categorical Data Analysis Using the SAS System. SAS Institute, Cary, NC.
421. Strom, B.L. (1987) Generic drug substitution revisited. NEJM, 316, 1456-1462.
422. Suganami, H. (2004) Points to notice and proposal drug induced QT interval prolongation - Is your correction good enough? Drug Information Association Meeting, www.diahome.org
423. Swallow, W., Monahan, J. (1984) Monte carlo comparison of ANOVA, MIVQUE, REML, and ML estimators of variance components. Technometrics, 26, 47-57.
424. Tanida, N. (2002) Ethical considerations for clinical trials in Asia. Drug Information Journal, 36, 41-9.
425. Temple, R. (1999) Are surrogate markers adequate to assess cardiovascular disease drugs? Journal of the American Medical Association, 282, 790-795.
426. Temple, R. (2003) Overview of the concept paper, history of the QT/TdP concern; Regulatory implications of QT prolongation. Presentations at Drug Information Agency/FDA Workshop, www.diahome.org
427. Thall, P., Cook, J. (2004) Dose-finding based on efficacy-toxicity trade-offs. Biometrics, 60, 684-693.
428. Ting, N., Burdick, R.K., Graybill, F.A., Jeyaratnam, S., Lu, TF. C. (1990) Confidence intervals on linear combinations of variance components that are unrestricted in sign. Journal of Statistical Computing and Simulation, 35, 135-143.
429. Tothfalusi, L., Endrenyi, L., Midha, K., Rawson, M., Hubbard, J. (2001) Evaluation of the bioequivalence of highly-variable drugs and drug products. Pharmaceutical Research, 18, 728-733.
430. Tothfalusi, L., Endrenyi, L. (2003) Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharmaceutical Research, 20, 382-389.
431. Tozer, T.N., Bois, F.Y., Hauck, W.W., Chen, M.L., Williams, R.L. (1996) Absorption rate versus exposure: Which is more useful for bioequivalence testing? Pharmaceutical Research, 13, 453-456.
432. Tozer, T.N., Hauck, W.W. (1997) Cmax/AUC, a commentary. Pharmaceutical Research, 14, 967-968.
433. Tsang, Y.C., Opo, R., Gordon, P., Hems, J., Spino, M. (1996) High variability in drug pharmacokinetics complicates determination of bioequivalence: Experience with Verapamil. Pharmaceutical Research, 13, 846-850.
434. Tudor, G., Koch, G. (1994) Review of nonparametric methods for the analysis of crossover studies. Statistical Methods in Medical Research, 3, 345-381.
435. Vonesh, E.F., Chinchilli, V.M. (1997) Linear and Nonlinear Models for the Analysis of Repeated Measurements. Marcel Dekker, New York.
436. Vuorinen, J. (1997) A practical approach for the assessment of bioequivalence under selected higher order cross-over designs. Statistics in Medicine, 16, 2229-2243.
437. Vuorinen, J., Turunen, J. (1996) A three step procedure for assessing bioequivalence in the general mixed linear framework. Statistics in Medicine, 15, 2635-2655.
438. Wakefield, J.C., Smith, A.F.-M., Racine-Poon, A., Gelfand, A.E. (1994) Bayesian analysis of linear and non-linear population models by using the Gibbs sampler. Applied Statistics, 43, 201-221.
439. Walpole, R.E., Myers, R.H., Myers, S.L. (1998) Probability and Statistics for Engineers and Scientists, 6ed. Prentice Hall, New Jersey.
440. Wang, C.M. (1990) On the lower bound of confidence coefficients for a confidence interval on variance components. Biometrics, 46, 187-192.
441. Wang, W. (1997) Optimal unbiased tests for equivalence in intrasubject variability. Journal of the American Statistical Association, 88, 939-946.
442. Wang, W. (1999) On testing for individual bioequivalence. Journal of the American Statistical Association, 94, 880-887.
443. Wang, Y. (1999) Use of jacknife influence profiles in bioequivalence evaluations. Pharmaceutical Science and Technology Today, 2, 152-159.
444. Welleck, S. (1993) Basing the analysis of comparative bioavailability trials on an individualized statistical definition of equivalence. Biometrical Journal, 35, 47-55.
445. Welleck, S. (1997) A comment on so called individual criteria of bioequivalence. Journal of Biopharmaceutical Statistics, 7, 17-21.
446. Welleck, S. (2000) On a reasonable disaggregate criterion of population bioequivalence admitting of resampling-free testing procedures. Statistics in Medicine, 19, 2755-2767.
447. Welleck, S. (2003) Testing Statistical Hypotheses of Equivalence. Chapman and Hall, London.
448. Welty, T.E., Pickering, P.R., Hale, B.C., Arazi, R. (1992) Loss of seizure control associated with generic substitution of carbamazepine. Annals of Pharmacotherapy, 26, 775-777.
449. Westfall, P. (1997) Multiple testing of general contrasts using logical constraints and correlations. Journal of the American Statistical Association, 92, 299-306.
450. Westfall, P., Tobias, R., Rom, D., Wolfinger, R., Hochberg, Y. (1999) Multiple Comparisons and Multiple Tests using SAS. SAS Institute, Cary, NC.
451. Westlake, W.J. (1972) Use of confidence intervals in analysis of comparative bioavailability trials. Journal of Pharmaceutical Sciences, 61, 1340-1341.
452. Westlake, W.J. (1979) Statistical aspects of comparative bioavilability trials. Biometrics, 35, 273-280.
453. Westlake, W.J. (1986) Bioavailability and bioequivalence of pharmaceutical formulations. In Biopharmaceutical Statistics for Drug Development, Peace, K. ed., 329-352. Marcel Dekker, New York.
454. Wetherill, G., Glazebrook, K. (1986) Sequential Methods in Statistics.Chapman and Hall, New York.
455. Whitehead, J. (1996) Sequential designs for equivalence studies. Statistics in Medicine, 15, 2703-2715.
456. Whitehead, J., Zhou, Y., Stallard, N., Todd, S., Whitehead, A. (2001) Learning from previous responses in phase 1 dose escalation studies. British Journal of Clinical Pharmacology, 52, 1-7.
457. Willavize, S., Morgenthein, E. (2005) Comparison of models for average bioequivalence in replicate designs. Proceedings of the American Statistical Association.
458. Williams, R.L., Adams, W., Chen, M.-L., Hare, D., Hussain, A., Lesko, L., Patnaik, R., Shah, V., and FDA Biopharmaceutics Coordinating Committee (2000a) Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? European Journal of Drug Metabolism and Pharmacokinetics, 25, 7-12.
459. Williams, R.L., Patnaik, R.N., Chen, M.-L. (2000b) The basis for individual bioequivalence. European Journal of Drug Metabolism and Pharmacokinetics, 25, 13-17.
460. Wolfinger, R., Tobias, R., Sall, J. (1994) Computing gaussian likelihoods and their derivatives for general linear mixed models. Siam J Sci Comput, 15, 1294-1310.
461. Wolfinger, R.D., Kass, R.E. (2000) Nonconjugate Bayesian analysis of variance component models. Biometrics, 56, 768-774.
462. Wysowski, D., Corken, A., Gallo-Torres, H., Talarico, L., Rodriguez, E. (2001) Postmarketing reports of QT prolongation and ventricular arrhythmia in association with Cisapride and FDA regulatory actions. American Journal of Gastroenterology, 96, 1698-1703.
463. Yacobi, A., Masson, E., Moros, D., Ganes, D., Lapointe, C., Abolfathi, Z., LeBel, M., Golander, Y., Doepner, D., Blumberg, T., Cohen, Y., Levitt, B. (2000) Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin. Journal of Clinical Pharmacology, 40, 826-835.
464. Yasuhara, H. (1994) Which is more important in pharmacokinetics:inter-ethnic variability or intra-ethnic variability. In Proceedings of the Second International Conference on Harmonisation, 1993, D’Arcy, PF., Harron, D., eds.
465. Yamaoka, K., Nakagawa, T., Uno, T. (1978) Statistical moments in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 6, 547-558.
466. Yee, K.F. (1986) The calculation of probabilities in rejecting bioequivalence. Biometrics, 42, 961-965.
467. Yeh, K.C., Kwan, K.C. (1978) A comparison of numerical integrating algorithms of trapezoidal, Legrange, and spline approximation. Journal of Pharmacokinetics and Biopharmaceutics, 6, 79-81.
468. Yuh, L., Beal, S., Davidian, M., Harrison, F., Hester, A., Kowalski, K., Vonesh, E., Wolfinger, R. (1994) Population pharmacokinetic-pharmacodynamic methodology and applications:A bibliography. Biometrics, 50, 566-575.
469. Zariffa, N., M.-D., Patterson, S.D., Boyle, D., Hyneck, H. (1998) Case Studies, comparison of the current and proposed bioequivalence criteria. FDA/AAPS Workshop on Bioavailability and Bioequivalence.
470. Zariffa, N., M.-D., Patterson, S.D. (1999) A case review on the topic of subject by formulation interaction. AAPS International workshop on Individual Bioequivalence: Realities and Implementation.
471. Zariffa, N., M.-D., Patterson, S.D. (2000) Learnings and recommendations for population and individual bioequivalence based on the analysis of replicate study designs. AAPS/FDA Workshop on Biopharmaceutics in the New Millennium: Regulatory Approaches to Bioavailability and Bioequivalence.
472. Zariffa, N., M.-D., Patterson, S.D., Boyle, D., Hyneck, H. (2000) Case studies, practical issues, and observations on population and individual bioequivalence. Statistics in Medicine, 19, 2811-2820.
473. Zariffa, N.M-D., Patterson, S.D. (2001) Population and individual bioequivalence: Lessons from real data and simulation studies. Journal of Clinical Pharmacology, 41, 811-822.